MedPath

Effect of a WeChat Platform-based Management Intervention on Blood Pressure Control

Not Applicable
Conditions
Hypertension
Interventions
Other: WeChat platform group
Registration Number
NCT04682015
Lead Sponsor
First Affiliated Hospital of Wenzhou Medical University
Brief Summary

WeChat is the largest and most popular social media platform in China, In this study, investigators will evaluate the use of management program delivered via WeChat platform in patients with hypertension.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
436
Inclusion Criteria
  • Patients aged ≥ 18 years with confirmed diagnosis of hypertension
  • Office systolic blood pressure (SBP)≥140 mmHg and/or diastolic blood pressure (DBP)≥90 mmHg, or ambulatory blood pressure monitoring (ABPM) indicating 24- hour SBP ≥130 mmHg and/or DBP ≥80 mmHg and/or daytime SBP ≥135 mmHg and/or DBP ≥85 mmHg and/or nocturnal SBP ≥120 mmHg and/or DBP ≥70 mmHg.
  • Patients have smart phone and often use WeChat to communicate with others (including written interaction)
  • Patients are willing and able to give informed consent for participation in the trial
Read More
Exclusion Criteria
  • Secondary hypertension
  • Hypertensive emergency: defined as severe elevations in BP (SBP ≥180 mmHg and/or DBP≥120mmHg) associated with evidence of new or worsening target organ damage, including hypertensive encephalopathy, intracranial hemorrhage, cerebral hemorrhage, subarachnoid hemorrhage, cerebral infarction, heart failure, acute coronary syndrome (unstable angina, acute myocardial infarction), aortic dissection, perioperative hypertension, preeclampsia, and eclampsia
  • Refractory hypertension: defined as failure to control BP despite lifestyle changes and use of at least 5 antihypertensive agents of different classes, including a thiazide-type diuretic and a mineralocorticoid receptor antagonist
  • Pregnancy or lactation or having pregnancy plan during the study period
  • Life expectancy less than 1 year
  • Participation in another clinical study or clinical trial in the 3 months prior to the confirmation of eligibility or current user of WeChat platform provided by hypertension center of the first affiliated hospital of Wenzhou medical university
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InterventionWeChat platform groupThe intervention group will be enrolled into WeChat platform. Participants will receive health education materials, monitor blood pressure at home and sent the blood pressure record to the platform and consult doctors online via platform.
Primary Outcome Measures
NameTimeMethod
Proportion with controlled blood pressure at 12 months (defined by ambulatory blood pressure monitoring )12 months

mean 24-hour ambulatory blood pressure monitoring (ABPM) \<130/80 mmHg, day time blood pressure \<135/85 mmHg, and nocturnal blood pressure \<120/70 mmHg

Secondary Outcome Measures
NameTimeMethod
Systolic blood pressure (mmHg) at 12 months12 months

Systolic blood pressure (mmHg) at 12 months

Medication adherence at 12 months12 months

Medication adherence will be measured by 8-item self-reported medication-taking scale

Diastolic blood pressure (mmHg) at 12 months12 months

Diastolic blood pressure (mmHg) at 12 months

© Copyright 2025. All Rights Reserved by MedPath